Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial
Catherine G. Ireland(Brigham and Women's Hospital), Carolyn Y. Ho(Brigham and Women's Hospital), Anna Axelsson Raja(Copenhagen University Hospital), Brian Claggett(National Heart Lung and Blood Institute), Ivan Wilmot(Cincinnati Children's Hospital Medical Center), Joseph W. Rossano(Children's Hospital of Philadelphia), Alexandre C. Pereira(University of Washington), E. John Orav(Harvard University), Anjali Owens(University of Pennsylvania), Amit R. Patel(University of Virginia), Jonathan H. Soslow(Vanderbilt University Medical Center), Henning Bundgaard(Copenhagen University Hospital), Matthew T. Wheeler(Stanford University), Kimberly Y. Lin(Children's Hospital of Philadelphia), Kenneth Zahka(Cleveland Clinic), Jason R. Becker(University of Pittsburgh), Matthew R.G. Taylor(University of Colorado Anschutz Medical Campus), Luisa Mestroni(University of Colorado Anschutz Medical Campus), Danielle S. Burstein(Children's Hospital of Philadelphia), Ilya Giverts(Massachusetts General Hospital), Sharlene M. Day(University of Pennsylvania), Richard G. Bach(Washington University in St. Louis), Mark W. Russell(Andover Eye Associates), Charles E. Canter(St. Louis Children's Hospital)
Cited by 6
Related Papers
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Truncations of Titin Causing Dilated Cardiomyopathy
|New England Journal of Medicine|2012|1.5k